Quiapeg Pharmaceuticals Holding AB (QUIA) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 6 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.06

Return on Equity

-310.49%

Price to Book

0.95

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2022)

Net Profit:

-5 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-72.97%

6 Months

-83.61%

1 Year

-93.51%

2 Years

-97.93%

3 Years

-99.98%

4 Years

-100.0%

5 Years

-100.0%

Quiapeg Pharmaceuticals Holding AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

0.00%

EBIT to Interest (avg)

-1.60

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.06

Sales to Capital Employed (avg)

0.56

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

4.99%

ROE (avg)

1.67%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.21

EV to EBIT

-0.50

EV to EBITDA

-0.63

EV to Capital Employed

1.21

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-243.57%

ROE (Latest)

-310.49%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bullish

Bollinger Bands

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'22 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2022 is 0.00% vs 0.00% in Dec 2021",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2022 is 30.43% vs -2.99% in Dec 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.80",
          "val2": "-5.30",
          "chgp": "47.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.10",
          "val2": "0.50",
          "chgp": "120.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.80",
          "val2": "-6.90",
          "chgp": "30.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -102.42% vs 17.91% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.30",
          "val2": "-13.40",
          "chgp": "15.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "1.00",
          "chgp": "-70.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-19.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-33.40",
          "val2": "-16.50",
          "chgp": "-102.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'22 - YoY

Dec'22

Dec'21

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.80

-5.30

47.17%

Interest

1.10

0.50

120.00%

Exceptional Items

0.00

Consolidate Net Profit

-4.80

-6.90

30.43%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2022 is 0.00% vs 0.00% in Dec 2021

Consolidated Net Profit

YoY Growth in quarter ended Dec 2022 is 30.43% vs -2.99% in Dec 2021

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-11.30

-13.40

15.67%

Interest

0.30

1.00

-70.00%

Exceptional Items

-19.50

0.00

Consolidate Net Profit

-33.40

-16.50

-102.42%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -102.42% vs 17.91% in Dec 2023

All Annual Results

Company CV

About Quiapeg Pharmaceuticals Holding AB

Quiapeg Pharmaceuticals Holding AB

Pharmaceuticals & Biotechnology

QuiaPEG Pharmaceuticals Holding AB is a Sweden-based biotechnology company. The Company develops improved versions of clinically validated biopharmaceutical drugs based on PEGylation technology platform. The Company’s technology is applicable on proteins, peptides and small molecules and offers a half-life extension platform consisting of covalent, as well as extended release PEGylation. The Company focuses on development of long-acting biopharmaceuticals for the treatment of metabolic disorders. The main project intends to reduce the frequent injection therapy by requiring significantly fewer injections. The Company offers out-licensing and partnering opportunities. It has a patent portfolio with patents pending and an approved the United States patent covering chemical linkers.

Company Coordinates

Company Details

Uppsala Business Park, Virdings Alle 32 B UPPSALA None : 754 50

Tel: 46 8 7780006

http://www.quiapeg.com/

Registrar Details